scholarly journals Pretreatment of outer membrane vesicle and subsequent infection with influenza virus induces a long-lasting adaptive immune response against broad subtypes of influenza virus

2021 ◽  
pp. 104878
Author(s):  
Chang-Ung Kim ◽  
Sukyeong Eo ◽  
Pureum Lee ◽  
Sang-Hyun Kim ◽  
Young Sang Kim ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Outer Membrane ◽  
Membrane Vesicle ◽  
Adaptive Immune Response ◽  
Outer Membrane Vesicle ◽  
Subsequent Infection ◽  
Adaptive Immune

Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac

Vaccine ◽  
2012 ◽  
Vol 30 (34) ◽  
pp. 5059-5062 ◽  
Author(s):  
François Caron ◽  
Valérie Delbos ◽  
Estelle Houivet ◽  
Ala-Eddine Deghmane ◽  
Jean-Philippe Leroy ◽  
...  
Keyword(s):  
Immune Response ◽  
Neisseria Meningitidis ◽  
Outer Membrane ◽  
Membrane Vesicle ◽  
Outer Membrane Vesicle ◽  
Before And After

scholarly journals Obesity Impairs the Adaptive Immune Response to Influenza Virus

2017 ◽  
Vol 14 (Supplement_5) ◽  
pp. S406-S409 ◽  
Author(s):  
William D. Green ◽  
Melinda A. Beck
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Adaptive Immune Response ◽  
Adaptive Immune

scholarly journals Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents

2006 ◽  
Vol 14 (1) ◽  
pp. 65-73 ◽  
Author(s):  
Dominique Boutriau ◽  
Jan Poolman ◽  
Ray Borrow ◽  
Jamie Findlow ◽  
Javier Diez Domingo ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Outer Membrane ◽  
Vaccine Coverage ◽  
Membrane Vesicle ◽  
Control Group ◽  
Outer Membrane Vesicle ◽  
Fourfold Increase ◽  
Randomized Controlled ◽  
Protective Antigens

ABSTRACT An experimental bivalent meningococcal outer membrane vesicle (OMV) vaccine (B:4:P1.19,15 and B:4:P1.7-2,4) has been developed to provide wide vaccine coverage particularly of the circulating strains in Europe. A randomized, controlled phase II study (study identification number, 710158/002; ClinicalTrials.gov identifier number, NCT00137917) to evaluate the immunogenicity and safety of three doses of the OMV vaccine when given to healthy 12- to 18-year-olds on a 0-2-4 month (n = 162) or 0-1-6 month schedule (n = 159). A control group received two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule (n = 157). Immune response, defined as a fourfold increase in serum bactericidal titer using a range of vaccine-homologous or PorA-related and heterologous strains, was determined for samples taken before and 1 month after vaccination; assays were performed at two laboratories. As measured at the GlaxoSmithKline (GSK) laboratory, the OMV vaccine induced an immune response against homologous or PorA-related strains (in at least 51% of subjects against strains of serosubtype P1.19,15 and at least 66% against strains of serosubtype P1.7-2,4) and against a set of three heterologous strains (in 28% to 46% of subjects). Both laboratories showed consistent results for immune response rates. The OMV vaccine had a similar reactogenicity profile for each schedule. Pain preventing normal activities occurred in approximately one-fifth of the subjects; this was significantly higher than in the control group. The immune responses induced by the bivalent OMV vaccine demonstrated the induction of bactericidal antibodies against the vaccine-homologous/PorA-related strains but also against heterologous strains, indicating the presence of protective antigens in OMVs and confirming the potential of clinical cross-protection.

Nasal priming with immunobiotic lactobacilli improves the adaptive immune response against influenza virus

2020 ◽  
Vol 78 ◽  
pp. 106115 ◽  
Author(s):  
Fernanda Raya Tonetti ◽  
Md. Aminul Islam ◽  
Maria Guadalupe Vizoso-Pinto ◽  
Hideki Takahashi ◽  
Haruki Kitazawa ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Adaptive Immune Response ◽  
Adaptive Immune

scholarly journals Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus

2010 ◽  
Vol 84 (13) ◽  
pp. 6687-6698 ◽  
Author(s):  
Hongyu Miao ◽  
Joseph A. Hollenbaugh ◽  
Martin S. Zand ◽  
Jeanne Holden-Wiltse ◽  
Tim R. Mosmann ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Epithelial Cells ◽  
Influenza A Virus ◽  
Half Life ◽  
Influenza A ◽  
Adaptive Immune Response ◽  
Biological Parameters ◽  
Data Set ◽  
Adaptive Immune

ABSTRACT Seasonal and pandemic influenza A virus (IAV) continues to be a public health threat. However, we lack a detailed and quantitative understanding of the immune response kinetics to IAV infection and which biological parameters most strongly influence infection outcomes. To address these issues, we use modeling approaches combined with experimental data to quantitatively investigate the innate and adaptive immune responses to primary IAV infection. Mathematical models were developed to describe the dynamic interactions between target (epithelial) cells, influenza virus, cytotoxic T lymphocytes (CTLs), and virus-specific IgG and IgM. IAV and immune kinetic parameters were estimated by fitting models to a large data set obtained from primary H3N2 IAV infection of 340 mice. Prior to a detectable virus-specific immune response (before day 5), the estimated half-life of infected epithelial cells is ∼1.2 days, and the half-life of free infectious IAV is ∼4 h. During the adaptive immune response (after day 5), the average half-life of infected epithelial cells is ∼0.5 days, and the average half-life of free infectious virus is ∼1.8 min. During the adaptive phase, model fitting confirms that CD8+ CTLs are crucial for limiting infected cells, while virus-specific IgM regulates free IAV levels. This may imply that CD4 T cells and class-switched IgG antibodies are more relevant for generating IAV-specific memory and preventing future infection via a more rapid secondary immune response. Also, simulation studies were performed to understand the relative contributions of biological parameters to IAV clearance. This study provides a basis to better understand and predict influenza virus immunity.

Sign in / Sign up

Export Citation Format

Share Document